首页 > 最新文献

Revista espanola de medicina nuclear e imagen molecular最新文献

英文 中文
Peritoneal carcinomatosis with PSMA-PET/TC (18F-DCFPyL). 腹腔癌伴PSMA-PET/TC (18F-DCFPyL)。
Pub Date : 2026-03-19 DOI: 10.1016/j.remnie.2026.500311
G Molina Mendoza, F Pena Pardo, M Contreras Ameduri, B Gonzalez García, V M Poblete García
{"title":"Peritoneal carcinomatosis with PSMA-PET/TC (<sup>18</sup>F-DCFPyL).","authors":"G Molina Mendoza, F Pena Pardo, M Contreras Ameduri, B Gonzalez García, V M Poblete García","doi":"10.1016/j.remnie.2026.500311","DOIUrl":"https://doi.org/10.1016/j.remnie.2026.500311","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500311"},"PeriodicalIF":0.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pheochromocytoma with sympathetic hyperactivity: a diagnostic challenge. 嗜铬细胞瘤伴交感神经亢进:一个诊断挑战。
Pub Date : 2026-03-19 DOI: 10.1016/j.remnie.2026.500312
D Tercero Garrido, A S De Agrela Serrao, M V Guiote Moreno, J Fernández Fernández, M Nicolas Aguado, J A Vallejo Casas
{"title":"Pheochromocytoma with sympathetic hyperactivity: a diagnostic challenge.","authors":"D Tercero Garrido, A S De Agrela Serrao, M V Guiote Moreno, J Fernández Fernández, M Nicolas Aguado, J A Vallejo Casas","doi":"10.1016/j.remnie.2026.500312","DOIUrl":"https://doi.org/10.1016/j.remnie.2026.500312","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500312"},"PeriodicalIF":0.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Impact of 18F-PSMA-1007 PET/MRI in staging Intermediate/ High-Risk Prostate Cancer Patients: Imaging Biomarkers and Radiomic Analysis Associated with Tumor Aggressiveness. 18F-PSMA-1007 PET/MRI对分期中/高危前列腺癌患者的治疗影响:与肿瘤侵袭性相关的成像生物标志物和放射组学分析
Pub Date : 2026-03-17 DOI: 10.1016/j.remnie.2026.500309
J R Garcia, L Pinilla, A Compte, N Garrido, L L Mont-Castro, S Ruiz, J Garcia Magro, J M Santabárbara, D Tovar, S Mourelo, M Soria, E Riera

Objective: To evaluate the impact of initial staging in prostate cancer patients using 18F-PSMA PET/MR and to analyze the prognostic value of pre-treatment PET/MRI imaging biomarkers.

Methods: Prospective study of 50 consecutive patients diagnosed with intermediate/high-risk prostate cancer. Simultaneous acquisition on PET/MR (SIGNA GE) 1 hour after intravenous administration of 370 ± 10% MBq of 18F-PSMA-1007: - Prostate (20 min): PET emission + mpMRI sequences: DIXON, T1, T2, DWI, DCE. - Whole-body (30 min): PET emission + MR sequences: DIXON, T1, T2, DWI, STIR. Consensus between nuclear medicine physician and radiologist for T, nodal, and metastatic staging. Visual interpretation. Treatment selection by multidisciplinary tumor board. SUV and ADC values were calculated. Pearson correlation analysis was performed. Radiomic analysis included extraction of 93 features: first-order and texture-based. Significant differentiation was assessed using ANOVA between two prognostic groups: (1) TxN0M0 or TxN1M0; (2) TxN1M1a or M1b.

Results: PET/MRI enabled comprehensive staging in a single session, classifying 28% of patients as T3b and detecting extraprostatic disease in 44% (28% oligometastatic, 16% polymetastatic). PET/MRI concordance for extracapsular extension and seminal vesicle infiltration was high in T3b (85.7%) but markedly lower in T3a (25%). SUVmax/ADC correlation was inverse and significant (p < 0.05). Texture features showed superior discriminative ability compared to conventional parameters, achieving an AUC of 0.79 for differentiating advanced T stages. Following PET/MR, 66% of patients underwent radical prostatectomy (with targeted lymphadenectomy in N1), 18% received image-guided radiotherapy, and 16% systemic therapy, without performing surgery in cases with extracapsular extension or metastatic disease.

Conclusion: PET/MRI with [18F]F-PSMA-1007 is a feasible and effective technique for initial staging of intermediate/high-risk prostate cancer, acting as a comprehensive "one-stop" diagnostic procedure. Its high sensitivity for nodal and bone disease, combined with integration of radiomic biomarkers, provides prognostic value and enables optimization of personalized therapeutic decisions.

目的:评价18F-PSMA PET/MR对前列腺癌患者初始分期的影响,分析治疗前PET/MRI成像生物标志物的预后价值。方法:对50例连续诊断为中/高危前列腺癌的患者进行前瞻性研究。18F-PSMA-1007静脉注射370±10% MBq后1小时PET/MR (SIGNA GE)同时采集:-前列腺(20分钟):PET发射+ mpMRI序列:DIXON、T1、T2、DWI、DCE。-全身(30分钟):PET发射+ MR序列:DIXON, T1, T2, DWI, STIR。核医学医师和放射科医师对T、淋巴结和转移分期的共识。目视判读。多学科肿瘤委员会选择治疗方案。计算SUV和ADC值。进行Pearson相关分析。放射组学分析包括提取93个特征:一阶和基于纹理的特征。采用方差分析(ANOVA)评估两个预后组之间的显著差异:(1)TxN0M0或TxN1M0;(2) TxN1M1a或M1b。结果:PET/MRI在一次治疗中实现了全面分期,28%的患者被分类为T3b, 44%的患者检测到前列腺外病变(28%的患者少转移,16%的患者多转移)。T3b囊外延伸和精囊浸润的PET/MRI一致性高(85.7%),而T3a明显低(25%)。结论:PET/MRI结合[18F]F-PSMA-1007是一种可行、有效的中高危前列腺癌初始分期技术,可作为一种全面的“一站式”诊断程序。它对淋巴结和骨病的高敏感性,结合放射组学生物标志物的整合,提供了预后价值,并使个性化治疗决策得以优化。
{"title":"Therapeutic Impact of 18F-PSMA-1007 PET/MRI in staging Intermediate/ High-Risk Prostate Cancer Patients: Imaging Biomarkers and Radiomic Analysis Associated with Tumor Aggressiveness.","authors":"J R Garcia, L Pinilla, A Compte, N Garrido, L L Mont-Castro, S Ruiz, J Garcia Magro, J M Santabárbara, D Tovar, S Mourelo, M Soria, E Riera","doi":"10.1016/j.remnie.2026.500309","DOIUrl":"https://doi.org/10.1016/j.remnie.2026.500309","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the impact of initial staging in prostate cancer patients using 18F-PSMA PET/MR and to analyze the prognostic value of pre-treatment PET/MRI imaging biomarkers.</p><p><strong>Methods: </strong>Prospective study of 50 consecutive patients diagnosed with intermediate/high-risk prostate cancer. Simultaneous acquisition on PET/MR (SIGNA GE) 1 hour after intravenous administration of 370 ± 10% MBq of 18F-PSMA-1007: - Prostate (20 min): PET emission + mpMRI sequences: DIXON, T1, T2, DWI, DCE. - Whole-body (30 min): PET emission + MR sequences: DIXON, T1, T2, DWI, STIR. Consensus between nuclear medicine physician and radiologist for T, nodal, and metastatic staging. Visual interpretation. Treatment selection by multidisciplinary tumor board. SUV and ADC values were calculated. Pearson correlation analysis was performed. Radiomic analysis included extraction of 93 features: first-order and texture-based. Significant differentiation was assessed using ANOVA between two prognostic groups: (1) TxN0M0 or TxN1M0; (2) TxN1M1a or M1b.</p><p><strong>Results: </strong>PET/MRI enabled comprehensive staging in a single session, classifying 28% of patients as T3b and detecting extraprostatic disease in 44% (28% oligometastatic, 16% polymetastatic). PET/MRI concordance for extracapsular extension and seminal vesicle infiltration was high in T3b (85.7%) but markedly lower in T3a (25%). SUVmax/ADC correlation was inverse and significant (p < 0.05). Texture features showed superior discriminative ability compared to conventional parameters, achieving an AUC of 0.79 for differentiating advanced T stages. Following PET/MR, 66% of patients underwent radical prostatectomy (with targeted lymphadenectomy in N1), 18% received image-guided radiotherapy, and 16% systemic therapy, without performing surgery in cases with extracapsular extension or metastatic disease.</p><p><strong>Conclusion: </strong>PET/MRI with [18F]F-PSMA-1007 is a feasible and effective technique for initial staging of intermediate/high-risk prostate cancer, acting as a comprehensive \"one-stop\" diagnostic procedure. Its high sensitivity for nodal and bone disease, combined with integration of radiomic biomarkers, provides prognostic value and enables optimization of personalized therapeutic decisions.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500309"},"PeriodicalIF":0.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147488541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal and Hematologic Toxicity Profile of [177] Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT): A Retrospective Cohort Study. [177] lu标记psma靶向放射治疗(177Lu-PSMA-RLT)的肾脏和血液毒性分析:一项回顾性队列研究。
Pub Date : 2026-03-16 DOI: 10.1016/j.remnie.2026.500306
Merve Yalçınkaya, Fadime Demir, Seyhan Karaçavuş, Mustafa Demir

Objective: This study aims to retrospectively evaluate the renal and hematologic toxicity profile of 177Lu-PSMA-RLT in patients with metastatic castration-resistant prostate cancer.

Methods: Renal function (GFR, BUN, and creatinine) and hematological parameters (hemoglobin, leukocyte, platelet) before and after treatment were examined in 41 patients who received 177Lu-PSMA-RLT at our clinic, and changes along with toxicity grades were determined. Additionally, pre-treatment PSMA PET/CT findings and other demographic and clinical data were assessed.

Results: In terms of renal toxicity, G0-G1 level toxicity was observed in 97.6% of cases, while G2 toxicity was observed in only one patient. This patient already had a low GFR before treatment and experienced only a 3-unit decrease. Regarding hematological toxicity, the rates of G3-4 toxicity were as follows: leukocytes 7.3%, hemoglobin 9.8%, platelets 7.3%.

Conclusion: No clinically significant nephrotoxicity was observed with 177Lu-PSMA-RLT. Hematologic toxicity is significant but manageable, and severe side effects are rare and within predictable limits.

目的:本研究旨在回顾性评估177Lu-PSMA-RLT对转移性去势抵抗性前列腺癌患者的肾脏和血液毒性。方法:对我院接受177Lu-PSMA-RLT治疗的41例患者治疗前后的肾功能(GFR、BUN、肌酐)和血液学参数(血红蛋白、白细胞、血小板)进行检测,并测定其随毒性分级的变化。此外,还评估了治疗前PSMA PET/CT结果以及其他人口统计学和临床数据。结果:在肾毒性方面,97.6%的病例出现G0-G1级毒性,仅1例出现G2级毒性。该患者在治疗前GFR已经很低,仅下降了3个单位。血液学毒性方面,G3-4毒性率分别为:白细胞7.3%,血红蛋白9.8%,血小板7.3%。结论:177Lu-PSMA-RLT未观察到明显的临床肾毒性。血液毒性是显著的,但可控的,严重的副作用是罕见的,在可预见的范围内。
{"title":"Renal and Hematologic Toxicity Profile of [177] Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT): A Retrospective Cohort Study.","authors":"Merve Yalçınkaya, Fadime Demir, Seyhan Karaçavuş, Mustafa Demir","doi":"10.1016/j.remnie.2026.500306","DOIUrl":"https://doi.org/10.1016/j.remnie.2026.500306","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to retrospectively evaluate the renal and hematologic toxicity profile of <sup>177</sup>Lu-PSMA-RLT in patients with metastatic castration-resistant prostate cancer.</p><p><strong>Methods: </strong>Renal function (GFR, BUN, and creatinine) and hematological parameters (hemoglobin, leukocyte, platelet) before and after treatment were examined in 41 patients who received <sup>177</sup>Lu-PSMA-RLT at our clinic, and changes along with toxicity grades were determined. Additionally, pre-treatment PSMA PET/CT findings and other demographic and clinical data were assessed.</p><p><strong>Results: </strong>In terms of renal toxicity, G0-G1 level toxicity was observed in 97.6% of cases, while G2 toxicity was observed in only one patient. This patient already had a low GFR before treatment and experienced only a 3-unit decrease. Regarding hematological toxicity, the rates of G3-4 toxicity were as follows: leukocytes 7.3%, hemoglobin 9.8%, platelets 7.3%.</p><p><strong>Conclusion: </strong>No clinically significant nephrotoxicity was observed with <sup>177</sup>Lu-PSMA-RLT. Hematologic toxicity is significant but manageable, and severe side effects are rare and within predictable limits.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500306"},"PeriodicalIF":0.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET/CT in Agressive Pericardial Mesothelioma. 18F-FDG PET/CT在侵袭性心包间皮瘤中的表现。
Pub Date : 2026-03-16 DOI: 10.1016/j.remnie.2026.500307
Busra Bozca, Nazli Altun Yologlu, Ozlem Ozmen
{"title":"<sup>18</sup>F-FDG PET/CT in Agressive Pericardial Mesothelioma.","authors":"Busra Bozca, Nazli Altun Yologlu, Ozlem Ozmen","doi":"10.1016/j.remnie.2026.500307","DOIUrl":"https://doi.org/10.1016/j.remnie.2026.500307","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500307"},"PeriodicalIF":0.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic pattern of Huntington´s disease on PET-TC and other imaging tests in Nuclear Medicine. 核医学中亨廷顿氏病的PET-TC及其他影像学检查的代谢模式
Pub Date : 2026-03-16 DOI: 10.1016/j.remnie.2026.500310
R González Couto, A Sanfiel Delgado, M R Malo de Molina Zamora, S Cifuentes Díaz, A E Jiménez Medina, M C Isla Gallego
{"title":"Metabolic pattern of Huntington´s disease on PET-TC and other imaging tests in Nuclear Medicine.","authors":"R González Couto, A Sanfiel Delgado, M R Malo de Molina Zamora, S Cifuentes Díaz, A E Jiménez Medina, M C Isla Gallego","doi":"10.1016/j.remnie.2026.500310","DOIUrl":"https://doi.org/10.1016/j.remnie.2026.500310","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500310"},"PeriodicalIF":0.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exceptional craniofacial uptake pattern on bone scintigraphy. 骨显像上异常的颅面摄取模式。
Pub Date : 2026-03-16 DOI: 10.1016/j.remnie.2026.500305
S de la Torre Fernández, B Aradas Cabado, A K Minguillan Van Kapel, D Castro Cardenas, A E Seva Delgado, C M Hernández Heredia
{"title":"Exceptional craniofacial uptake pattern on bone scintigraphy.","authors":"S de la Torre Fernández, B Aradas Cabado, A K Minguillan Van Kapel, D Castro Cardenas, A E Seva Delgado, C M Hernández Heredia","doi":"10.1016/j.remnie.2026.500305","DOIUrl":"https://doi.org/10.1016/j.remnie.2026.500305","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500305"},"PeriodicalIF":0.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective sentinel lymph node biopsy in a tumor on axillary ectopic breast tissue 腋窝异位乳腺组织肿瘤前哨节的选择性活检。
Pub Date : 2026-03-01 Epub Date: 2025-08-30 DOI: 10.1016/j.remnie.2025.500207
R. González Couto, C.M. Carballo Menayo, A. Sanfiel Delgado, F.J. González Hernández, S. Cifuentes Díaz, M.C. Isla Gallego
{"title":"Selective sentinel lymph node biopsy in a tumor on axillary ectopic breast tissue","authors":"R. González Couto,&nbsp;C.M. Carballo Menayo,&nbsp;A. Sanfiel Delgado,&nbsp;F.J. González Hernández,&nbsp;S. Cifuentes Díaz,&nbsp;M.C. Isla Gallego","doi":"10.1016/j.remnie.2025.500207","DOIUrl":"10.1016/j.remnie.2025.500207","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500207"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of extremely rare testicular cancer metastasis to the duodenum with 18F-FDG PET/CT 极罕见睾丸癌转移至十二指肠的18F-FDG PET/CT检测。
Pub Date : 2026-03-01 Epub Date: 2025-09-17 DOI: 10.1016/j.remnie.2025.500230
Muhammet Fatih Beytur , Enver Yarıkkaya , Sevim Baykal Koca , Göksel Alçın , Elife Akgün , Erkan Erkan , Esra Arslan
{"title":"Detection of extremely rare testicular cancer metastasis to the duodenum with 18F-FDG PET/CT","authors":"Muhammet Fatih Beytur ,&nbsp;Enver Yarıkkaya ,&nbsp;Sevim Baykal Koca ,&nbsp;Göksel Alçın ,&nbsp;Elife Akgün ,&nbsp;Erkan Erkan ,&nbsp;Esra Arslan","doi":"10.1016/j.remnie.2025.500230","DOIUrl":"10.1016/j.remnie.2025.500230","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500230"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[18F]FDG PET/CT in pulmonary Castleman's disease [18F]肺Castleman病的FDG PET/CT诊断。
Pub Date : 2026-03-01 Epub Date: 2025-09-04 DOI: 10.1016/j.remnie.2025.500209
H.Y. Zhang , X. Yang
{"title":"[18F]FDG PET/CT in pulmonary Castleman's disease","authors":"H.Y. Zhang ,&nbsp;X. Yang","doi":"10.1016/j.remnie.2025.500209","DOIUrl":"10.1016/j.remnie.2025.500209","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500209"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista espanola de medicina nuclear e imagen molecular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1